GlaxoSmithKline PLC — Regulatory Filings 2021

Apr 12, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2021

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc (the ' Company ')

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D Redfern | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Strategy Officer | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of the financial
instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN:
GB0009252882 | |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 April 2021, on Ordinary Shares
held within an ISA | |
| c) | Price(s) and
volume(s) | Price(s) | Volume(s) |
| | | £13.1380 | 38 |
| d) | Aggregated information Aggregated volume Price | N/A (single transaction) | |
| e) | Date
of the transaction | 2021-04-09 | |
| f) | Place of the
transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms V Whyte | |
| --- | --- | --- | --- |
| b) | Position/status | Company Secretary | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description of the financial
instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN:
GB0009252882 | |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 April 2021, on Ordinary Shares
held within an ISA | |
| c) | Price(s) and
volume(s) | Price(s) | Volume(s) |
| | | £13.1380 | 33 |
| d) | Aggregated information Aggregated volume Price | N/A (single transaction) | |
| e) | Date
of the transaction | 2021-04-09 | |
| f) | Place of the
transaction | London Stock Exchange (XLON) | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: April
12, 2021
By:/s/ VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break